MATTE', Alessandro
 Distribuzione geografica
Continente #
NA - Nord America 3.241
EU - Europa 3.155
AS - Asia 2.354
SA - Sud America 374
Continente sconosciuto - Info sul continente non disponibili 108
AF - Africa 71
OC - Oceania 11
Totale 9.314
Nazione #
US - Stati Uniti d'America 3.170
RU - Federazione Russa 1.261
SG - Singapore 879
CN - Cina 688
GB - Regno Unito 652
IT - Italia 352
BR - Brasile 304
VN - Vietnam 285
HK - Hong Kong 189
SE - Svezia 175
FR - Francia 151
IE - Irlanda 142
DE - Germania 141
FI - Finlandia 110
KR - Corea 61
JP - Giappone 51
UA - Ucraina 42
ID - Indonesia 39
IN - India 34
AR - Argentina 33
CA - Canada 28
MX - Messico 27
NL - Olanda 25
AT - Austria 23
BD - Bangladesh 19
BE - Belgio 17
TR - Turchia 16
NG - Nigeria 15
ES - Italia 13
EG - Egitto 12
PL - Polonia 12
IQ - Iraq 11
AU - Australia 10
EC - Ecuador 10
PK - Pakistan 10
UZ - Uzbekistan 10
ZA - Sudafrica 10
MA - Marocco 9
TW - Taiwan 9
GR - Grecia 8
BJ - Benin 7
CL - Cile 7
VE - Venezuela 6
CO - Colombia 5
CZ - Repubblica Ceca 5
JO - Giordania 5
NP - Nepal 5
OM - Oman 5
TG - Togo 5
CH - Svizzera 4
HU - Ungheria 4
KG - Kirghizistan 4
KZ - Kazakistan 4
LT - Lituania 4
MY - Malesia 4
PY - Paraguay 4
AL - Albania 3
AZ - Azerbaigian 3
CR - Costa Rica 3
DZ - Algeria 3
ET - Etiopia 3
IL - Israele 3
BA - Bosnia-Erzegovina 2
BO - Bolivia 2
DO - Repubblica Dominicana 2
EU - Europa 2
KH - Cambogia 2
LB - Libano 2
LK - Sri Lanka 2
NI - Nicaragua 2
PA - Panama 2
PH - Filippine 2
RO - Romania 2
SA - Arabia Saudita 2
TN - Tunisia 2
TT - Trinidad e Tobago 2
UY - Uruguay 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AE - Emirati Arabi Uniti 1
AF - Afghanistan, Repubblica islamica di 1
BB - Barbados 1
BH - Bahrain 1
BN - Brunei Darussalam 1
BT - Bhutan 1
BY - Bielorussia 1
DK - Danimarca 1
GE - Georgia 1
GH - Ghana 1
IR - Iran 1
JM - Giamaica 1
KE - Kenya 1
LI - Liechtenstein 1
LV - Lettonia 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
PE - Perù 1
PR - Porto Rico 1
PS - Palestinian Territory 1
PT - Portogallo 1
QA - Qatar 1
Totale 9.202
Città #
Southend 538
Singapore 453
Moscow 430
Ashburn 401
Chandler 340
San Jose 287
Dallas 239
Jacksonville 189
Hong Kong 184
Verona 173
Ann Arbor 154
Dublin 142
Beijing 139
Council Bluffs 120
Houston 89
The Dalles 83
Woodbridge 78
Wilmington 69
Ho Chi Minh City 67
New York 64
Los Angeles 60
Dong Ket 57
Lawrence 50
Princeton 50
Jinan 48
Tokyo 45
Hanoi 39
Nanjing 39
Helsinki 37
Jakarta 36
São Paulo 33
Hebei 32
Shenyang 31
Buffalo 28
Munich 28
Milan 25
Santa Clara 22
Seattle 21
Lancaster 19
London 19
Redondo Beach 19
Collegeville 18
Columbus 18
Falls Church 18
Ningbo 18
Boardman 17
Brussels 17
Changsha 17
Hangzhou 17
Redmond 17
Sindelfingen 17
Nanchang 16
Orem 16
Turku 16
Vienna 16
Zhengzhou 16
Guangzhou 15
Tianjin 15
Nuremberg 14
Frankfurt am Main 12
Montreal 12
Rome 12
San Francisco 12
Taiyuan 12
Abuja 11
Chicago 11
Campinas 10
Haikou 10
Jiaxing 10
Stockholm 10
Warsaw 10
Chennai 9
Manchester 9
Taizhou 9
Bologna 8
Tashkent 8
Washington 8
Atlanta 7
Baghdad 7
Belo Horizonte 7
Cotonou 7
Haiphong 7
Johannesburg 7
Lanzhou 7
Mexico City 7
Phoenix 7
Redwood City 7
Toronto 7
Brooklyn 6
Cagliari 6
Cairo 6
Cambridge 6
Catanzaro 6
Dongguan 6
Norwalk 6
Rio de Janeiro 6
Amman 5
Ankara 5
Boston 5
Cincinnati 5
Totale 5.603
Nome #
Hypoxia-reperfusion affects osteogenic lineage and promotes sickle cell bone disease 294
Impaired pro‐resolving mechanisms promote abnormal NETosis , fueling autoimmunity in sickle cell disease 275
CD66b-CD64dimCD115- cells in the human bone marrow represent neutrophil-committed progenitors 259
Fyn kinase is a novel modulator of erythropoietin signaling and stress erythropoiesis. 245
Two-photon microscopy imaging of thy1GFP-M transgenic mice: a novel animal model to investigate brain dendritic cell subsets in vivo 229
A new molecular link between defective autophagy and erythroid abnormalities in chorea-acanthocytosis 222
TREATMENT OF SKELETAL DISEASES WITH A NATURALLY DERIVED ANTIOXIDANT AND BISPHOSPHONATE EMBEDDED NANOPARTICLES 218
A Selective Oral GLYT1 Inhibitor, Improves Anemia and Red Cell Survival in a Mouse Model of Beta-Thalassemia 216
Protease inhibitors-based therapy induces acquired spherocytic-like anemia and ineffective erythropoiesis in chronic HCV patients 200
Membrane association of peroxiredoxin-2 in red cells is mediated by the N-terminal cytoplasmic domain of band3 193
New Therapeutic Options for the Treatment of Sickle Cell Disease. 191
Erythrocyte membrane changes of chorea-acanthocytosis are the result of altered Lyn kinase activity 189
The interplay between peroxiredoxin-2 and Nrf2 is important in limiting oxidative mediated dysfunction in b-thalassemic erythropoiesis 189
Heat shock protein-27, 70 and peroxiredoxin-II show molecular chaperone function in sickle red cells: evidences from transgenic sickle cell mouse model 186
Peroxiredoxin-2: A Novel Factor Involved in Iron Homeostasis 186
NCOA4 Deficiency Impairs Systemic Iron Homeostasis 185
Data demonstrating the role of peroxiredoxin 2 as important anti-oxidant system in lung homeostasis. 185
Factor H interfers with the adhesion of sickle red cells to vascular endothelium: a novel disease modulating molecule 183
Oxidative stress and b-thalasssemic erythroid cells behind the molecular defect 179
IN ChAc RED CELLS THE ABNORMALLY ACTIVATED LYN AFFECTS ANKYRIN MULTIPROTEIN COMPLEXES AND IS INHIBITED BY DASATINIB 178
Band 3 Erythrocyte Membrane Protein Acts as Redox Stress Sensor Leading to Its Phosphorylation by p (72) Syk 176
Therapeutic targeting of Lyn kinase to treat chorea-acanthocytosis 173
S-nitrosylation of peroxiredoxin II E promotes peroxynitrite-mediated tyrosine nitration 172
PEROXIREDOXIN-2: A NOVEL REGULATOR OF IRON HOMEOSTASIS IN INEFFECTIVE ERYTHROPOIESIS 171
Resveratrol accelerates erythroid maturation by activation of FoxO3 and ameliorates anemia in beta-thalassemic mice 170
Dietary w-3 fatty acids protect against vasculopathy in a transgenic mouse model for sickle cell disease. 169
Deoxygenation affects tyrosine phosphoproteome of red cell membrane from patients with sickle cell disease 168
Integrated proteomic analysis of normal and diseased red cells. Role of physiological stresses in erythrocyte signaling pathways 167
Emerging drugs in randomized controlled trials for sickle cell disease: are we on the brink of a new era in research and treatment? 167
Proteomic analysis of S-nitrosylated proteins in Arabidopsis thaliana undergoing hypersensitive response 159
Increased levels of ERFE-encoding FAM132B in patients with congenital dyserythropoietic anemia type II 155
Proteomic and functional analysis of tyrosinephosphorylated red cell membrane proteins in mouse lacking SRC-family-kinases 147
Adaptative Up-Regulation of PRX2 and PRX5 Expression Characterizes Brain from a Mouse Model of Chorea-Acanthocytosis 146
Pharmacological inhibition of calpain-1 prevents red cell dehydration and reduces Gardos channel activity in a mouse model of sickle cell disease 146
The novel role of peroxiredoxin-2 in red cell membrane protein homeostasis and senescence. 146
Effects of hypoxia–reoxygenation stimuli on renal redox status and nuclear factor erythroid 2-related factor 2 pathway in sickle cell SADmice 144
Tyrosine phosphorylation modulates peroxiredoxin-2 activity in normal and diseased red cells 143
Peroxiredoxin-2 plays a pivotal role as multimodal cytoprotector in the early phase of pulmonary hypertension 142
Oxidation and erythropoiesis 142
Fyn specifically Regulates the activity of red cell glucose-6-phosphate-dehydrogenase 140
Epeleuton, a novel synthetic ω-3 fatty acid, reduces hypoxia/ reperfusion stress in a mouse model of sickle cell disease 139
The Novel Role That Nrf2 Plays in Erythropoiesis during Aging 139
Performance of a novel sieving matrix of Poly(vinyl alcohol)ACRYLAMIDE copolymer in elecrophoretic separations of high molecular weight proteins from red cell membrane. 137
Resolvin D1 and Resolvin D2 Protect Against Hypoxia/Reoxygenation Induced Lung and Kidney Damage in a Sickle Cell Mouse Model of Acute Vaso-Occlusive Crisis 136
Bitopertin, a selective oral GLYT1 inhibitor, improves anemia in a mouse model of β-thalassemia 135
Pathologic angiogenesis in the bone marrow of humanized sickle cell mice is reversible by blood transfusion 135
Oxidized and poorly glycosylated band 3 is selectively phosphorylated by Syk kinase to form large membrane clusters in normal and G6PD-deficient red blood cells 133
Resolution of sickle cell disease-associated inflammation and tissue damage with 17R-resolvin D1. 133
Peroxiredoxin-2 (Prx2) expression is increased in beta thalassemic mouse red cells but displaced from the membrane as marker of oxidative stress 129
An Oral Carbon Monoxide-Releasing Molecule Protects against Acute Hyper-hemolysis in Sickle Cell Disease 128
Pesticide toxicogenomics across scales: in vitro transcriptome predicts mechanisms and outcomes of exposure in vivo 120
Red Blood Cell Homeostasis: Pharmacological Interventions to Explore Biochemical, Morphological and Mechanical Properties. 115
Oxidation Impacts the Intracellular Signaling Machinery in Hematological Disorders 112
Mitapivat metabolically reprograms human beta-thalassemic erythroblasts, increasing their responsiveness to oxidation 95
Plasma peroxiredoxin changes and inflammatory cytokines support the involvement of neuro-inflammation and oxidative stress in Autism Spectrum Disorder 91
Pharmacological Inhibition of Calpain-1 Prevents Red Cell Dehydration and Reduces Gardos Channel Activity in a Mouse Model of Sickle Cell Disease. Identification of Druggable Protease Target 51
PEROXIREDOXIN-2 (Prx2) MEMBRANE DISPLACEMENT IS A NEW ADDITIONAL FACTOR to the SEVERITY of beta-THALASSEMIC MOUSE RED CELL MEMBRANE DAMAGE 41
Totale 9.314
Categoria #
all - tutte 30.086
article - articoli 25.838
book - libri 0
conference - conferenze 3.777
curatela - curatele 0
other - altro 471
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 60.172


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022412 0 130 14 34 21 11 14 25 35 17 18 93
2022/2023983 62 132 82 150 90 240 8 37 98 33 32 19
2023/2024536 22 40 39 61 66 78 25 35 9 14 109 38
2024/20251.426 76 64 49 242 77 96 129 69 209 81 100 234
2025/20263.805 264 176 246 572 1.069 274 368 202 235 248 49 102
2026/2027115 39 76 0 0 0 0 0 0 0 0 0 0
Totale 9.314